At a glance
- Originator GlaxoSmithKline
- Class Antidementias; Neuroprotectants
- Mechanism of Action Amyloid inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 02 Oct 2001 No-Development-Reported for Alzheimer's disease in USA (unspecified route)
- 24 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
- 29 Jul 1998 Preclinical development for Alzheimer's disease in USA (unspecified route)